5th Chronic Kidney Disease Drug Development Summit

The CKD Drug Development Summit is uniquely positioned to de-risk drug development in cardiorenal disorders and provide strategic insight into paving the way to regulatory approval.

Dr Kathryn Garner will be presenting the following talk:

Primary kidney cells for modelling Chronic Kidney Disease in vitro

• Human podocytes maintain high levels of key podocyte markers, including nephrin, podocin, WT1, CD2AP.
• Well-validated Podocyte Toxicity Assay senses injury through barrier integrity (TEER) measures and passage of fluorescently-labelled dextran molecules.
• Disease modelling in podocytes, proximal tubule cells and renal fibroblasts with monitoring of fibrosis readouts – matrix deposition – using high content imaging.

Discover more about our glomerulus model